Baidu
map

Communications Biology:“超广域眼底病筛查系统” 检查只需 1 分钟

2020-01-14 朱汉斌 邰梦云 中国科学报

中山大学中山眼科中心副主任林浩添团队基于 10 万余例超广域眼底彩照,研发出全球首个 “超广域人工智能眼底病筛查系统”,检测准确率达到 98% 以上。相关研究近日发表在《自然》杂志子刊《生物通信》上。

中山大学中山眼科中心副主任林浩添团队基于 10 万余例超广域眼底彩照,研发出全球首个 “超广域人工智能眼底病筛查系统”,检测准确率达到 98% 以上。相关研究近日发表在《自然》杂志子刊《生物通信》上。

眼底是眼球的后段,由视网膜、视乳头、黄斑和视网膜中央动静脉等组成。传统眼底检查一般需要散瞳,耗时耗力;而传统眼底照相范围仅有 30°~45° 视野,可能出现漏诊。现有的人工智能眼底检查系统基于传统眼底照相,主要检查眼底后极部视网膜病变,观察周边视网膜的能力很有限。

林浩添团队采用的超广域眼底照相,检查过程免散瞳,且成像范围达 200°~240°,是传统眼底照相范围的 5 倍以上,能更早、更准确地检查出全周视网膜病变,并能根据病变特征给予相应医学指导,尽可能挽救患者视功能。

林浩添表示,由于检查过程只需 1 分钟左右,此系统还可以应用于大规模人群的眼病筛查。

该团队成员李中文表示,该系统可对图像质量进行实时、准确监控。如果超过 3 次拍摄图片质量仍不提高,代表有可能是眼前段屈光间质混浊造成,则自动给出转诊建议。

该团队成员郭翀介绍,目前针对超广域眼底照相机,尚无图片质量监控系统。而 “超广域人工智能眼底病筛查系统” 的推出,让临床诊疗更高效。

“尽管超广域眼底彩照具有足够视野范围,但准确解读此眼底图像也需要眼科医生经过专业培训和较长时间经验的积累。” 林浩添表示,对于缺乏专业眼底病医生的医疗机构、体检中心,这款系统可以高效、精确地完成眼底病筛查。

原始出处:

Li, Z., Guo, C., Nie, D. et al. Deep learning for detecting retinal detachment and discerning macular status using ultra-widefield fundus images. Commun Biol 3, 15 (2020) doi:10.1038/s42003-019-0730-x.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1767736, encodeId=f7701e67736b9, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jul 07 20:17:00 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918964, encodeId=4d79191896403, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 08 12:17:00 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087647, encodeId=c9e7208e647b1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Apr 20 21:17:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458389, encodeId=9711145838932, content=<a href='/topic/show?id=12e5e27551d' target=_blank style='color:#2F92EE;'>#眼底病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72755, encryptionId=12e5e27551d, topicName=眼底病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3296055952, createdName=huiwelcome, createdTime=Thu Jan 16 05:17:00 CST 2020, time=2020-01-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1767736, encodeId=f7701e67736b9, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jul 07 20:17:00 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918964, encodeId=4d79191896403, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 08 12:17:00 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087647, encodeId=c9e7208e647b1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Apr 20 21:17:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458389, encodeId=9711145838932, content=<a href='/topic/show?id=12e5e27551d' target=_blank style='color:#2F92EE;'>#眼底病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72755, encryptionId=12e5e27551d, topicName=眼底病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3296055952, createdName=huiwelcome, createdTime=Thu Jan 16 05:17:00 CST 2020, time=2020-01-16, status=1, ipAttribution=)]
    2020-10-08 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1767736, encodeId=f7701e67736b9, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jul 07 20:17:00 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918964, encodeId=4d79191896403, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 08 12:17:00 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087647, encodeId=c9e7208e647b1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Apr 20 21:17:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458389, encodeId=9711145838932, content=<a href='/topic/show?id=12e5e27551d' target=_blank style='color:#2F92EE;'>#眼底病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72755, encryptionId=12e5e27551d, topicName=眼底病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3296055952, createdName=huiwelcome, createdTime=Thu Jan 16 05:17:00 CST 2020, time=2020-01-16, status=1, ipAttribution=)]
    2020-04-20 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1767736, encodeId=f7701e67736b9, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jul 07 20:17:00 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918964, encodeId=4d79191896403, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 08 12:17:00 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087647, encodeId=c9e7208e647b1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Apr 20 21:17:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458389, encodeId=9711145838932, content=<a href='/topic/show?id=12e5e27551d' target=_blank style='color:#2F92EE;'>#眼底病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72755, encryptionId=12e5e27551d, topicName=眼底病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3296055952, createdName=huiwelcome, createdTime=Thu Jan 16 05:17:00 CST 2020, time=2020-01-16, status=1, ipAttribution=)]

相关资讯

从儿童近视到糖尿病视网膜病变,你需要知道多少?|2019CCOS

2019全国眼科学术大会热点话题,小M带你抢先看!

赵家良教授丨从视觉损伤原因的变化看我国眼健康的进展

2019年9月5日,由中华医学会主办的第二十四次全国眼科学术大会在苏州拉开帷幕,梅斯医学小编也第一时间奔赴现场,为大家带来学术报道。我国“十三五”眼健康规划强调:“眼健康是国民健康的中药组成部分,包括盲在内的视觉损伤严重影响人民群众的身体健康和生活质量,加重家庭和社会负担,威胁社会经济生产活动,是涉及民生的重大公共卫生问题和社会问题。”本次大会上,中国医学科学院北京协和医院的赵家良教授为大家详细讲

难治性眼底病在我国实现微创治疗突破

长期以来,难治性眼底病是全球不可逆性致盲的主要原因之一。近日在北京召开的2017年中华医学科技奖颁奖大会上,“难治性眼底病的发病机理与临床系列研究”项目荣获一等奖,它实现了“安全微创治疗”的突破,相关成果已应用于临床推广。

这些症状是患上眼底病的**警告,警惕“眼底三患”

“眼底三患”个个都是夺人视力的“杀手”。其中黄斑变性堪称第一杀手,其次是糖网、视网膜血管阻塞。黄斑对于视力的重要性,一言以蔽之,“视力诚可贵,黄斑价更高”。

Baidu
map
Baidu
map
Baidu
map